Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 15/20 | 0.73 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29019410 | 1.00 | PTGIR (0.73) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL23851986 | 1.00 | PTGIR (0.73) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL1118836 | 0.96 | PTGIR (0.79) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL1118834 | 0.96 | PTGIR (0.79) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL29019403 | 0.89 | PTGIR (0.68) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL29019417 | 0.88 | PTGIR (0.64) | PTGIRPTGDRCHRM2CHRM1CHRM3 | |
| SCHEMBL29019412 | 0.88 | PTGIR (0.73) | PTGIRPTGDRPTGER4PTGER3PTGER2 | |
| SCHEMBL29019401 | 0.87 | PTGIR (0.62) | PTGIRPTGDRCHRM2CHRM1CHRM3 | |
| SCHEMBL29019378 | 0.87 | PTGIR (0.62) | PTGIRPTGDRPTGER1PTGER4PTGER3 | |
| SCHEMBL29019390 | 0.86 | PTGIR (0.67) | PTGIRPTGDRPTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4349330-A2 | METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOR | Arena Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-3209291-B1 | METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOR | ARENA PHARM INC (US) | 2023-12-06 | — | — | EP | claimed |
| US-11826471-B2 | Compositions comprising PGI2-receptor agonists and processes for the preparation thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | claimed |
| CN-110582271-B | Compositions comprising PGI2 receptor agonists and methods of making the same | 阿瑞那制药公司 | 2022-06-14 | — | — | CN | claimed |
| CN-114452279-A | Methods of treating conditions associated with the PGI2 receptor | 艾尼纳制药公司 | 2022-05-10 | — | — | CN | claimed |
| CN-110582271-A | Compositions comprising PGI2 receptor agonists and methods of making the same | 阿瑞那制药公司 | 2019-12-17 | — | — | CN | claimed |
| CN-114452279-A | Methods of treating conditions associated with the PGI2 receptor | 艾尼纳制药公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114452279-A | Methods of treating conditions associated with the PGI2 receptor | 艾尼纳制药公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3884934-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| CN-110691612-A | Methods of treating PAH using RALINEPAG in combination with other agents | 阿瑞那制药公司 | 2020-01-14 | — | — | CN | disclosed |
| CN-110582271-A | Compositions comprising PGI2 receptor agonists and methods of making the same | 阿瑞那制药公司 | 2019-12-17 | — | — | CN | disclosed |
| CN-110582271-A | Compositions comprising PGI2 receptor agonists and methods of making the same | 阿瑞那制药公司 | 2019-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826471-B2 | Compositions comprising PGI2-receptor agonists and processes for the preparation thereof | PTGIR, PTGER1, PTGDR | PTGIR 1/4885PTGDR 3/4885PTGER1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.